**FOI Ref: 6604**

**Category(ies): Clinical - Drugs**

**Subject: Usage of Intra-vitreal Injections or Implants May - August 2022**

**Date Received: 09/09/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| 1. How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from May to August 2022:
* Aflibercept
* Bevacizumab
* Brolucizumab
* Dexamethasone
* Faricimab
* Ranibizumab - Lucentis
* Ranibizumab – Ongavia
 | Please note the below figures are for May, June and July. The August figures are not yet available.* Aflibercept – 522
* Bevacizumab – 0
* Brolucizumab – 41
* Dexamethasone – 2
* Faricimab – 0
* Ranibizumab – Lucentis – 626
* Ranibizumab – Ongavia – 0
 |
| 1. Please provide the number of injections/implants by eye condition for the four-month period from May to August 2022.

|  |  |
| --- | --- |
| **Number of Injections/Implants: May - August 2022**Please note the below figures are for May, June and July. The August figures are not yet available. |   |
|   |   |   |   |
| **Treatment** | **Eye Conditions** |
| Wet Age-Related Macular Degeneration (wAMD) | Diabetic Macular Oedema (DMO) | Retinal Vein Occlusion (RVO) |
| Aflibercept  |  270 | 118 | 132 |
| Bevacizumab  |   |   |   |
| Brolucizumab   |  41 |   |   |
| Dexamethasone   |   |   |  2 |
| Faricimab |   |   |   |
| Ranibizumab - Lucentis |  362 | 122 | 140 |
| Ranibizumab - Ongavia |   |   |   |

 |